sponsored

Q&A: The paradigm shift in diabetes treatment

And the role of the newer glucose lowering agents in CVD

Sponsored

	hero.jpg

This content is independently produced by Australian Doctor Group with a grant from Astra Zeneca.

Type 2 diabetes mellitus (T2DM) patients with established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors are benefiting from some of the newer glucose lowering agents on the market.

ADG talks to cardiologist, Associate Professor, John Amerena about the importance of earlier prescribing of sodium-glucose cotransporter 2

Latest

Trending